Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael P Thirlwell

Showing results (1-10 of 4) with videos related to

Pageof 1
Sort By:
Seminars in Oncology|April 16, 2002
Radioembolization for hepatic metastasesMilton J Herba, Michael P Thirlwell
Anticancer Research|April 9, 2013
Response to chemotherapy in metastatic colorectal cancer after exposure to oxaliplatin in the adjuvant settingLouis-Charles Moreau, Raghu Rajan, Michael P Thirlwell, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 16, 2002
Randomized, open-label, phase III study of a 28-day oral regimen of eniluracil plus fluorouracil versus intravenous fluorouracil plus leucovorin as first-line therapy in patients with metastatic/advanced colorectal cancerRichard L Schilsky, Jeremey Levin, William H West, et al.
NPJ Breast Cancer|May 21, 2021
NRG Oncology/NSABP B-47 menstrual history study: impact of adjuvant chemotherapy with and without trastuzumabPatricia A Ganz, Reena S Cecchini, Louis Fehrenbacher, et al.
Pageof 1

Showing results (1-10 of 4) with videos related to

Sort By:
Pageof 1
Seminars in Oncology|April 16, 2002
Radioembolization for hepatic metastasesMilton J Herba, Michael P Thirlwell
Anticancer Research|April 9, 2013
Response to chemotherapy in metastatic colorectal cancer after exposure to oxaliplatin in the adjuvant settingLouis-Charles Moreau, Raghu Rajan, Michael P Thirlwell, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 16, 2002
Randomized, open-label, phase III study of a 28-day oral regimen of eniluracil plus fluorouracil versus intravenous fluorouracil plus leucovorin as first-line therapy in patients with metastatic/advanced colorectal cancerRichard L Schilsky, Jeremey Levin, William H West, et al.
NPJ Breast Cancer|May 21, 2021
NRG Oncology/NSABP B-47 menstrual history study: impact of adjuvant chemotherapy with and without trastuzumabPatricia A Ganz, Reena S Cecchini, Louis Fehrenbacher, et al.
Pageof 1